Disease · MONDO_0005096
Comparisons in its trials13
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 13 of 13
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm I (Chemo +/- Bevacizumab) vs Arm II (Chemo, Cetuximab, +/- Bevacizumab): deaths from any cause | 593 of 657 | 570 of 656 | 1,313 | NCT00946712 | Trial comparisons |
| Arm I (Chemo +/- Bevacizumab) vs Arm II (Chemo, Cetuximab, +/- Bevacizumab): serious adverse events | 66 of 632 | 97 of 627 | 1,259 | NCT00946712 | Trial comparisons |
| Sorafenib + C/P vs Placebo + C/P: serious adverse events | 272 of 463 | 195 of 459 | 922 | NCT00300885 | Trial comparisons |
| Pembrolizumab vs Standard Treatment: Number of Participants Who Experienced At Least One Adverse Event (AE) in All Participants | 240 of 246 | 227 of 234 | 480 | NCT02252042 | Trial comparisons |
| Pembrolizumab vs Standard Treatment: Number of Participants Who Discontinued Study Treatment Due to an AE in All Participants | 30 of 246 | 36 of 234 | 480 | NCT02252042 | Trial comparisons |
| Pembrolizumab vs Standard Treatment: Number of Participants Who Experienced At Least One AE in Participants With PD-L1 ≥1% CPS | 193 of 195 | 178 of 183 | 378 | NCT02252042 | Trial comparisons |
| Pembrolizumab vs Standard Treatment: Number of Participants Who Discontinued Study Treatment Due to an AE in Participants With PD-L1 ≥1% CPS | 25 of 195 | 29 of 183 | 378 | NCT02252042 | Trial comparisons |
| Group 1 vs Group 2: serious adverse events | 30 of 72 | 20 of 65 | 137 | NCT00573131 | Trial comparisons |
| Arm A vs Arm B: deaths from any cause | 4 of 19 | 2 of 17 | 36 | NCT03738228 | Trial comparisons |
| Arm A vs Arm B: serious adverse events | 6 of 19 | 7 of 17 | 36 | NCT03738228 | Trial comparisons |
| Arm I: Standard of Care Therapy + Placebo Testosterone vs Arm II: Standard of Care Therapy + Testosterone: deaths from any cause | 0 of 12 | 0 of 12 | 24 | NCT00878995 | Trial comparisons |
| Arm I: Standard of Care Therapy + Placebo Testosterone vs Arm II: Standard of Care Therapy + Testosterone: serious adverse events | 6 of 12 | 6 of 12 | 24 | NCT00878995 | Trial comparisons |
| Arm I: Standard of Care Therapy + Placebo Testosterone vs Arm II: Standard of Care Therapy + Testosterone: 1-year Survival | 7 of 12 | 6 of 10 | 22 | NCT00878995 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005096/comparisons